Literature DB >> 20192803

From allergen genes to allergy vaccines.

Rudolf Valenta1, Fatima Ferreira, Margarete Focke-Tejkl, Birgit Linhart, Verena Niederberger, Ines Swoboda, Susanne Vrtala.   

Abstract

IgE-mediated allergy is a hypersensitivity disease affecting more than 25% of the population. The structures of the most common allergens have been revealed through molecular cloning technology in the past two decades. On the basis of this knowledge of the sequences and three-dimensional structures of culprit allergens, investigators can now analyze the immune recognition of allergens and the mechanisms of allergic inflammation in allergic patients. Allergy vaccines have been constructed that are able to selectively target the aberrant immune responses in allergic patients via different pathways of the immune system. Here we review various types of allergy vaccines that have been developed based on allergen structures, results from their clinical application in allergic patients, and future strategies for allergen-specific immunotherapy and allergy prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20192803     DOI: 10.1146/annurev-immunol-030409-101218

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  76 in total

1.  Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer.

Authors:  Raffaela Campana; Susanne Vrtala; Bernhard Maderegger; Yuliya Dall'Antonia; Domen Zafred; Katharina Blatt; Harald Herrmann; Margarete Focke-Tejkl; Ines Swoboda; Sandra Scheiblhofer; Anna Gieras; Angela Neubauer; Walter Keller; Peter Valent; Josef Thalhamer; Susanne Spitzauer; Rudolf Valenta
Journal:  Mol Immunol       Date:  2010-11-18       Impact factor: 4.407

2.  Anti-TCRβ mAb induces long-term allograft survival by reducing antigen-reactive T cells and sparing regulatory T cells.

Authors:  Y Miyahara; M Khattar; P M Schroder; B Mierzejewska; R Deng; R Han; W W Hancock; W Chen; S M Stepkowski
Journal:  Am J Transplant       Date:  2012-03-15       Impact factor: 8.086

3.  Development of a rice-based peptide vaccine for Japanese cedar and cypress pollen allergies.

Authors:  Fumio Takaiwa; Lijun Yang
Journal:  Transgenic Res       Date:  2014-03-18       Impact factor: 2.788

Review 4.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

5.  Epitope Mapping of Rhi o 1 and Generation of a Hypoallergenic Variant: A CANDIDATE MOLECULE FOR FUNGAL ALLERGY VACCINES.

Authors:  Gaurab Sircar; Kuladip Jana; Angira Dasgupta; Sudipto Saha; Swati Gupta Bhattacharya
Journal:  J Biol Chem       Date:  2016-06-28       Impact factor: 5.157

6.  Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy.

Authors:  Birgit Linhart; Margarete Focke-Tejkl; Milena Weber; Meena Narayanan; Angela Neubauer; Hannes Mayrhofer; Katharina Blatt; Christian Lupinek; Peter Valent; Rudolf Valenta
Journal:  J Immunol       Date:  2015-03-18       Impact factor: 5.422

Review 7.  Next generation immunotherapy for tree pollen allergies.

Authors:  Yan Su; Eliezer Romeu-Bonilla; Teri Heiland
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 8.  The History of IgE: From discovery to 2010.

Authors:  S G O Johansson
Journal:  Curr Allergy Asthma Rep       Date:  2011-04       Impact factor: 4.806

9.  A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.

Authors:  Katharina Marth; Isabella Breyer; Margarete Focke-Tejkl; Katharina Blatt; Mohamed H Shamji; Janice Layhadi; Anna Gieras; Ines Swoboda; Domen Zafred; Walter Keller; Peter Valent; Stephen R Durham; Rudolf Valenta
Journal:  J Immunol       Date:  2013-02-25       Impact factor: 5.422

Review 10.  Modified Allergens for Immunotherapy.

Authors:  Pattraporn Satitsuksanoa; Anna Głobińska; Kirstin Jansen; Willem van de Veen; Mübeccel Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-16       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.